All In Biotech

Drug Trial Radar · NCT04858256

Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms

Phase 2, Open Label, Multicenter Study of Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms

Last checked: Nov 20, 2026Latest source record: Jan 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Mar 29, 2023

Primary completion

Nov 2027

Study completion Nov 2028

Sponsor

Lead sponsor
University of Michigan Rogel Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institutes of Health (NIH); National Cancer Institute (NCI); Hoosier Cancer Research Network; CTI BioPharma
First posted
Apr 26, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to determine the effectiveness of the study drug pacritinib in people with relapsed or refractory lymphoproliferative disorders.

Conditions

  • T-Cell Neoplasm
  • Lymphoproliferative Disorders

Interventions

  • PacritinibDrug

    Pacritinib will be dosed at 200mg twice daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall response rate (ORR)Time frame: Up to 2 years

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Not yet recruiting

  • University of Michigan Rogel Cancer Center

    Ann Arbor, Michigan · Recruiting

  • Duke Cancer Institute

    Durham, North Carolina · Recruiting

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio · Recruiting

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.